Abstract 130P
Background
At the population level, it is useful to estimate the liver cancer risk based on lifestyle factors and regular biomarkers to encourage high-risk people to be screened. Therefore, we conducted the current study to develop a prediction model for the stratification of liver cancer risk among the general population in China.
Methods
112 440 subjects aged 20-80 years from Kailuan Cohort were included in the current study. A total of 326 incident primary liver cancer occurred during 913 078.51 person-years of follow-up. We used the Cox proportional hazards regression model to obtain coefficients for each predictor in the 8-year prediction models among a random two thirds of participants. The prediction models were validated in the remaining one third of participants. Hosmer-Lemeshow’s statistic and Harrell’s C-index were used to evaluate calibration and discrimination, respectively.
Results
A full prediction model that comprised of nine predictors, including age, sex, smoking pack-years, alcohol drinking, tea consumption, diabetes and fasting blood glucose (FBG) level, total cholesterol (TC), alanine aminotransferase (ALT), and hepatitis B virus surface antigen (HBsAg), was derived. The model showed good calibration (χ2=3.57, P = 0.89) and discrimination (Harrell’s C-index=0.85; 95% confidence interval [CI]: 0.81, 0.88) in the validation data set.
Conclusions
A practical liver prediction model based on accessible indicators combined with lifestyle factors, regular blood biomarkers, and hepatitis virus status was developed, which allows to stratify the risk of liver cancer among the general population. Because the factors in this model are able to be acquired from questionnaire and blood detection, it has great potential to be translated into practical use for public health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R& D Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract